Assessment of levothyroxine sodium bioavailability: Recommendations for an improved methodology based on the pooled analysis of eight identically designed trials with 396 drug exposures

Clinical Pharmacokinetics

Volumn 43, Issue 14, 2004, Pages 1037-1053

  Walter Sack, Ingeborg ^a   Clanget, Christof ^a   Ding, Reinhard ^a   Goeggelmann, Christoph ^a   Hinke, Vera ^a   Lang, Matthias ^a   Pfeilschifter, Johannes ^a   Tayrouz, Yorki ^a   Wegscheider, Karl ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HENNING; LEVOTHYROXINE SODIUM;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG PROTEIN BINDING; HEAT SENSITIVITY; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; METHODOLOGY; MICTURITION DISORDER; NERVOUSNESS; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SWEATING; TACHYCARDIA; THYROXINE BLOOD LEVEL;

AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE I; CROSS-OVER STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS; SAMPLE SIZE; SEASONS; THERAPEUTIC EQUIVALENCY; THYROXINE;

EID: 10044237745     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200443140-00006     Document Type: Article

References (46)

1. Cooper DS. Subclinical hypothyroidism. N Engl J Med 2001; 345: 260-5
2. Toft AD. Thyroxine therapy. N Engl J Med 1994; 331: 174-80
3. Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. N Engl J Med 1987; 316: 764-70
4. Olveira G, Almaraz MC, Soriguer F, et al. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma. Clin Endocrinol 1997; 46: 707-11
5. Lee M. Equivalence of levothyroxine tablets [letter]. Drug Intell Clin Pharm 1983; 17: 265.
6. Ramos-Gabatin A, Jacobson JM, Young RL. In vivo comparison of levothyroxine preparations. JAMA 1982; 247: 203-5
7. Jacobson JM, Ramos-Gabatin A, Young RL, et al. Nonequality of brand name thyroxine preparations [letter]. JAMA 1980; 243: 733
8. Stoffer SS. Drug substitution [letter]. JAMA 1979; 242: 1257
9. Stoffer SS. Substitution of levothyroxine products [letter]. JAMA 1979; 241: 1229
10. Drug Bioequivalence Study Panel. Drug bioequivalence: recommendations to the Office of Technology Assessment, Congress of the United States. J Pharmacokinet Biopharm 1974; 2: 433-66
11. Barr WH. Bioavailability of oral solid dosage forms and clinical response to drug therapy. In: Swarbrick J, editor. Current concepts in the pharmaceutical sciences: dosage form design and bioavailability. Philadelphia (PA): Lea & Febiger, 1973: 31-75
12. Ball P, Klinger W, Strubelt O. Untersuchungen zur relativen Bioverfügbarkeit von Laevothyroxin-Na nach oraler Gabe. Nuc-Compact 1987; 18: 92-6
13. Berg JA, Mayor GA. A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthyroid® and Levoxine®. J Clin Pharmacol 1993; 33: 1135-40
14. Spencer CA, LoPresti JS, Nicoloff JT, et al. Multiphasic thyrotropin responses to thyroid hormone administration in man. J Clin Endocrinol Metab 1995; 80: 854-9
15. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977; 26: 1-8
16. Wenzel KW, Meinhold H. Evidence of lower toxicity during thyroxine suppression after a single 3-mg 1-thyroxine dose: comparison to the classical 1-triiodothyronine test for thyroid suppressibility. J Clin Endocrinol Metab 1974; 38: 902-5
17. Wallack MS, Adelberg HM, Nicoloff JT. A thyroid suppression test using a single dose of L-thyroxine. N Engl J Med 1970; 283: 402-5
18. European Union guideline. Investigation of bioavailability and bioequivalence [online]. Available from URL: http.//pharmacos.eudra.org/F2/ eudralex/vol-3/pdfs-en/3ccl5aen.pdf [Accessed 2004 Oct 7]
19. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf [Accessed 2004 Oct 7]
20. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: levothyroxine sodium tablets: in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing [online]. Available from URL: http://www.fda.gov/cder/guidance/3645fnl.pdf [Accessed 2004 Oct 7]
21. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products: general considerations [online]. Available from URL: http://www.fda.gov/cder/guidance/4964dft.pdf [Accessed 2004 Oct 7]
22. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: statistical approaches to establishing bioequivalence [online]. Available from URL: http://www.fda.gov/cder/guidance/3616fnl.htm [Accessed 2004 Oct 7]
23. Piketty ML, d'Herbomez M, Le Guillouzic D, et al. Clinical comparison of three labelled-antibody immunoassays of free triiodothyronine. Clin Chem 1996; 42: 933-41
24. Price A, Bennett K, Giles M, et al. The ACS: 180 as a thyroid function test analyzer. Clin Chem Enzym Comm 1995; 6: 373-84
25. Liewendahl K, Melamies L, Helenius T, et al. Automated and manual serum free thyroxine assays evaluated with equilibrium dialysis. Scand J Clin Lab Invest 1994; 54: 347-51
26. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med 1995; 14: 2057-79
27. Senn S. Cross-over trials in clinical research. Chichester: Wiley, 1993
28. Goeggelmann C, Clanget C, Ding R, et al. Bioequivalence assessment of endogenous compounds like hormones: eight levothyroxine (L-T4) formulations [abstract]. Eur J Clin Pharmacol 2002; 58: S94
29. Vaisman M, Spina LDC, Eksterman LF, et al. Comparative bioavailability of two oral L-thyroxine formulations after multiple dose administration in patients with hypothyroidism and its relation with therapeutic endpoints and dissolution profiles. Arzneimittel Forschung 2001; 51: 246-52
30. Förster G, Hansen C, Mörsch F, et al. Bioäquivalenz eines Kombinationspräparates aus Levothyroxin und Jodid im Vergleich zum Monopräparat Levothyroxin. Med Klin (Munich) 1998; 93: 401-6
31. Dong BJ, Hauck WW, Gambertoglio JG, et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 1997; 277: 1205-13
32. Hennessey JV, Evaul JE, Tseng YC, et al. L-thyroxine dosage: a re-evaluation of therapy with contemporary preparations. Ann Intern Med 1986; 105: 11-5
33. Hennessey JV, Burman KD, Wartowsky L. The equivalency of two L-thyroxine preparations. Ann Intern Med 1985; 102: 770-3
34. Wenzel KW, Mehrländer U. Wirksamkeitsunterschiede von Levothyroxin-Präparaten. Dtsch Med Wochenschr 1988; 113: 53-8
35. Klein I. Evaluation of bioequivalence and efficacy of L-thyroxine preparations in the treatment of human thyroid disease [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/03/briefing/ 3926B2_03_King%20Pharmaceutical-Backgrounder.pdf [Accessed 2004 Oct 7]
36. DeGroot L. Letter presented at the FDA Advisory Committee for Pharmaceutical Science Meeting scheduled for March 13, 2003 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3926OPH2_10_DeGroot. pdf [Accessed 2004 Oct 7]
37. Hershman JM. Letter presented at the FDA Advisory Committee for Pharmaceutical Science Meeting scheduled for March 13, 2003 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3926OPH2_11_Hershman. pdf [Accessed 2004 Oct 7]
38. Baskin HJ. Letter presented at the FDA Advisory Committee for Pharmaceutical Science Meeting scheduled for March 13, 2003 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3926OPH2_16_Baskin.pdf [Accessed 2004 Oct 7]
39. Trantow T, Herzog R, Fuder H, et al. A pilot study on the determination of the relative bioavailability of levo-thyroxine. Methods Find Exp Clin Pharmacol 1995; 17: 333-43
40. Behall KM, Scholfield DJ, Hallfrisch JG, et al. Seasonal variation in plasma glucose and hormone levels in adult men and women. Am J Clin Nutr 1984; 40: 1352-6
41. Levine M, Duffy L, Moore DC, et al. Acclimation of a non-indigenous sub-artic population: seasonal variation in thyroid function in interior Alaska. Comp Biochem Physiol 1995; 111A: 209-14
42. Smals AGH, Ross HA, Kloppenborg PWC. Seasonal variation in serum T3 and T4 levels in man. J Clin Endocrinol Metab 1977; 44: 998-1001
43. Hegedüs L, Rasmussen N, Knudsen N. Seasonal variation in thyroid size in healthy males. Horm Metab Res 1987; 19: 391-2
44. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP). Points to consider on adjustment for baseline covariates [online]. Available from URL: http://www.emea.eu.int/pdfs/ human/ewp/286399en.pdf [Accessed 2004 Oct 7]
45. Food and Drug Administration, Advisory Committee for Pharmaceutical Science. Transcript of meeting on bioequivalence/bioavailability of endogenous products, March 13, 2003 [online]. Available from URL: http://www.fda.gov/ohrms/ dockets/ac/03/transcripts/3926T2.htm [Accessed 2004 Oct 7]
46. Stockigt J. Testing the bioavailability of oral 1-thyroxine by studying its absorption: smoke or mirrors? Thyroid 2004; 14: 167-8